Targeting the vasculature of solid tumors

[1]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[3]  K. Alitalo,et al.  Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas. , 1994, Cancer research.

[4]  L. Zardi,et al.  The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis , 1994, International journal of cancer.

[5]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[6]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[7]  F. Burrows,et al.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[9]  D. Ruiter,et al.  A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. , 1993, The Journal of investigative dermatology.

[10]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Partanen,et al.  Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. , 1992, Blood.

[12]  Y. Watanabe,et al.  A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. , 1992, Cancer research.

[13]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[14]  K. Plate,et al.  Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[15]  S. Rockman,et al.  Endoglin: a 180‐kD endothelial cell and macrophage restricted differentiation molecule , 1992, Clinical and experimental immunology.

[16]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[17]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[18]  G. Jaffe,et al.  Inhibition of Human Corneal Epithelium with Immunotoxin 454A12-rRA , 1992, Cornea.

[19]  D. Hatchell,et al.  Inhibition of human subconjunctival fibroblast proliferation by immunotoxin. , 1992, Investigative ophthalmology & visual science.

[20]  J. Partanen,et al.  A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains , 1992, Molecular and cellular biology.

[21]  J. V. van Mourik,et al.  Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.

[22]  J. Winer,et al.  Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. , 1992, The Journal of clinical investigation.

[23]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[24]  A. Saalmüller,et al.  Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. , 1991, Leukemia.

[25]  H. Dvorak,et al.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. , 1991, Cancer cells.

[26]  S. Kennel,et al.  Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts. , 1991, Cancer research.

[27]  H. Dvorak,et al.  Penetration of Tumor Tissue by Antibodies and Other Immunoproteins , 1991, Annals of the New York Academy of Sciences.

[28]  K. Foon,et al.  Overview of monoclonal antibodies in the diagnosis and therapy of cancer. , 1991, Cancer investigation.

[29]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .

[30]  L. Houston,et al.  Selective inhibition of growing pigment epithelial cells by a receptor-directed immunotoxin. , 1990, Investigative ophthalmology & visual science.

[31]  A. Montag,et al.  In Situ Distribution of the β-Subunit of Platelet-derived Growth Factor Receptor in Nonneoplastic Tissue and in Soft Tissue Tumors , 1990 .

[32]  G. Jaffe,et al.  Antitransferrin receptor immunotoxin inhibits proliferating human retinal pigment epithelial cells. , 1990, Archives of ophthalmology.

[33]  M. Letarte,et al.  Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. , 1990, The Journal of biological chemistry.

[34]  V. Diehl,et al.  Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. , 1990, Cancer research.

[35]  M. Edidin,et al.  A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. , 1990, Journal of immunology.

[36]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[38]  D. Newell,et al.  Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. , 1988, Cancer research.

[39]  R. W. Baldwin,et al.  Therapeutic strategies with monoclonal antibodies and immunoconjugates. , 1988, Immunology.

[40]  M. Letarte,et al.  Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. , 1988, Journal of immunology.

[41]  O. Fodstad,et al.  Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. , 1988, Cancer research.

[42]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[43]  G. Lui,et al.  Use of immunotoxin to inhibit proliferating human corneal endothelium. , 1988, Investigative ophthalmology & visual science.

[44]  R. Warnke,et al.  Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. , 1987, Blood.

[45]  S. Goerdt,et al.  A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non‐reactive with normal adult tissues , 1986, International journal of cancer.

[46]  J. Taylor‐Papadimitriou,et al.  Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. , 1986, Cancer research.

[47]  J. Uhr,et al.  Purification of ricin A1, A2, and B chains and characterization of their toxicity. , 1986, The Journal of biological chemistry.

[48]  D. Ruiter,et al.  Monoclonal antibody PAL-E specific for endothelium. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[49]  J. Denekamp.  Vasculature as a Target for Tumour Therapy , 1984 .

[50]  E. Jaffe.  Biology of Endothelial Cells , 1984, Developments in Cardiovascular Medicine.

[51]  C. Maass,et al.  Variable expression of Ia antigens on the vascular endothelium of mouse skin allografts , 1983, Nature.

[52]  J. Hilton,et al.  Effect of plasma and carboxylesterase on the stability, mutagenicity, and DNA cross-linking activity of some direct-acting N-nitroso compounds. , 1983, Cancer research.

[53]  J. Denekamp,et al.  Endothelial-cell proliferation in experimental tumours. , 1982, British Journal of Cancer.

[54]  D. Gospodarowicz,et al.  The identification and localization of fibronectin in cultured corneal endothelial cells: cell surface polarity and physiological implications. , 1979, Experimental eye research.